Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 58,500 shares, a drop of 17.1% from the November 30th total of 70,600 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 173,800 shares, the short-interest ratio is currently 0.3 days.

Trinity Biotech Stock Performance

Shares of TRIB stock traded down $0.01 on Friday, hitting $0.80. The stock had a trading volume of 131,284 shares, compared to its average volume of 412,086. Trinity Biotech has a 52-week low of $0.75 and a 52-week high of $3.55. The firm has a market capitalization of $6.11 million, a price-to-earnings ratio of -0.35 and a beta of 0.97. The stock’s 50 day moving average is $1.28 and its 200-day moving average is $1.86.

Hedge Funds Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 359,810 shares of the company’s stock after acquiring an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned approximately 4.72% of Trinity Biotech worth $390,000 at the end of the most recent quarter. 78.97% of the stock is owned by institutional investors and hedge funds.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.